Questions and Answers on Prothrombin Time Standardisation in Oral Anticoagulant Control

Summary

One of the reasons why oral anticoagulants fell into disrepute is the absence of internationally accepted standardised procedures for controlling the level of anticoagulatiori. This deplorable situation resulted in over- and under-coagulation and uncertainty in the therapeutic range. International conformity can now be obtained by using an International Normalised Ratio (INR) which is derived from the individual result obtained in a given plasma sample and the International Sensitivity Index (ISI) of the tissue thromboplastin reagent used. Any thromboplastin reagent can be calibrated against an international primary or secondary W.H.O. reference preparation, so as to obtain its International Sensitivity Index. The new system of reporting the level of anticoagulation was designed and can only safely be applied in patients taking oral anticoagulants.

Keywords

Prothrombin time - Oral anticoagulants - International normalised ratio - International sensitivity index - Standardisation

• References

• 1 Quick AJ, Stanley-Brown M, Bancroft FW. A study of the coagulation defect in hemophilia and in jaundice. Am J Med Sci 1935; 190: 501-511
• 2 Evatt BL, Brogan D, Triplett DA, Waters G. Effect of thromboplastin and instrumentation on the prothrombin time test. Clin Lab Haematol 1981; 3: 331-342
• 3 van den Besselaar AMHP, Evatt BL, Brogan DR, Triplett DA. Proficiency testing and standardization of prothrombin time: effect of thromboplastin, instrumentation and plasma. Am J Clin Pathol 1984; 82: 688-699
• 4 Conley CL, Morse WI. Thromboplastin factors in the estimation of prothrombin concentration. Am J Med Sci 1948; 215: 158-164
• 5 Merskey C, Scholtz E. Technical objectives in the control of anticoagulant therapy. Br J Haematol 1955; 1: 308-322
• 6 Verstraete M, Clark PA, Wright IS. Use of different tissue thromboplastins in the control of anticoagulant therapy. Circulation 1957; 16: 213-226
• 7 Biggs R, Denson KWE. Standardization of the one-stage prothrombin time for the control of anticoagulant therapy. Br Med J 1967; 1: 84-88
• 8 International Committee on Thrombosis and Haemostasis and International Committee for Standardization in Haematology. Prothrombin time standardization: Report of the Expert Panel on Anticoagulant Control. Thromb Haemostas 1979; 42: 1073-1114
• 9 Loeliger EA, Lewis SM. Progress in laboratory control of oral anticoagulants. Lancet 1982; 2: 318-320
• 10 WHO Expert Committee on Biological Standardization. 33rd Report. WHO Technical Report Series 1983; 687: 81-105
• 11 Kirkwood TBL. Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb Haemostas 1983; 49: 238-244
• 12 van den Besselaar AMHP, Loeliger EA, Poller L, Thomson JM, Tomenson JA. Standardisation of oral anticoagulant treatment. Br Med J 1984; 288: 486-487
• 13 van den Besselaar AMHP, Gralnick HR, Lewis SM. (Eds). Thromboplastin calibration and oral anticoagulant control. Martinus Nijhoff Publishers; La Haye and Boston: 1984
• 14 Thomson JM, Tomenson JA, Poller L. The calibration of the second primary international reference preparation for thromboplastin (Thromboplastin, Human, Plain, coded BCT/253). Thromb Haemostas 1984; 52: 336-342
• 15 Hermans J, van den Besselaar AMHP, Loeliger EA, van der Velde EA. A collaborative calibration study of reference materials for thromboplastins. Thromb Haemostas 1983; 50: 712-717
• 16 International Committee for Standardization in Haematology and International Committee on Thrombosis and Haemostasis. ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control. Thromb Haemostas 1985; 53: 155-156
• 17 Cornbleet PJ, Gochman N. Incorrect least-squares regression coefficients in method comparison analysis. Clin Chem 1979; 25: 432-438
• 18 Patefield WM. On the information matrix in the linear functional relationship problem. Applied Statistics 1977; 26: 69-70
• 19 Poller L. A national standard for anticoagulant therapy. The Manchester Comparative Reagent. Lancet 1967; 1: 491-493
• 20 Taberner DA, Poller L, Burslem RW, Jones JB. Oral anticoagulants controlled by the British comparative thromboplastin versus low-dose heparin in prophylaxis of deep vein thrombosis. Br Med J 1978; 1: 272-274
• 21 Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980; 2: 989-994
• 22 Hull R, Hirsh J, Jay R. et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982; 307: 1676-1681
• 23 Francis CW, Marder JD, Evarts Mc C, Yaukoolbodi S. Two-step warfarin therapy. Prevention of postoperative venous thrombosis without excessive bleeding. JAMA 1983; 249: 374-378
• 24 Loeliger EA, van den Besselaar AMHP, Lewis SM. Reliability and clinical impact of the normalisation of the prothrombin times in oral anticoagulant control. Thromb Haemostas 1985; 53: 148-154
• 25 Sixty Plus Reinfarction Study Research Group. Risks of long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1982; 1: 64-68
• 26 Wintzen AR, Tijssen JGP. Subdural haematoma and oral anticoagulant therapy. Arch Neurol 1982; 39: 69-72
• 27 Wintzen AR, De Jonge H, Loeliger EA, Bots GTAM. The risk of intracerebral hemorrhage during oral anticoagulant treatment; a population study. Ann Neurol 1984; 16: 553-558
• 28 Starr H, Rhoades P, Lam-Po-Tang PRLC, Archer GT. Prothrombin times: an evaluation of four thromboplastins and four machines. Pathology 1980; 12: 567-574
• 29 Zucker S, Brosious E, Cooper GR. One-stage Prothrombin Time Survey. Am J Clin Pathol 1970; 53: 340-347